BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36138075)

  • 1. Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
    Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
    Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
    J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characterization of Peritoneal Mesotheliomas.
    Offin M; Yang SR; Egger J; Jayakumaran G; Spencer RS; Lopardo J; Nash GM; Cercek A; Travis WD; Kris MG; Ladanyi M; Sauter JL; Zauderer MG
    J Thorac Oncol; 2022 Mar; 17(3):455-460. PubMed ID: 34648949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
    Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
    Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS signaling in malignant pleural mesothelioma.
    Marazioti A; Krontira AC; Behrend SJ; Giotopoulou GA; Ntaliarda G; Blanquart C; Bayram H; Iliopoulou M; Vreka M; Trassl L; Pepe MAA; Hackl CM; Klotz LV; Weiss SAI; Koch I; Lindner M; Hatz RA; Behr J; Wagner DE; Papadaki H; Antimisiaris SG; Jean D; Deshayes S; Grégoire M; Kayalar Ö; Mortazavi D; Dilege Ş; Tanju S; Erus S; Yavuz Ö; Bulutay P; Fırat P; Psallidas I; Spella M; Giopanou I; Lilis I; Lamort AS; Stathopoulos GT
    EMBO Mol Med; 2022 Feb; 14(2):e13631. PubMed ID: 34898002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
    Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
    Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
    Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
    Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features.
    Michal M; Kravtsov O; Ross JS; Skanderová D; Martínek P; Mosaieby E; Mata DA; Williams EA; Hung YP
    Genes Chromosomes Cancer; 2023 May; 62(5):267-274. PubMed ID: 36515470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
    Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.